Matrix metalloproteinases of human NK cells

In Vivo

Volumn 14, Issue 1, 2000, Pages 269-276

  Albertsson, Per ^a   Kim, Myoung H ^b   Jonges, Liesbeth E ^c   Kitson, Richard P ^b   Kuppen, Peter J K ^c   Johansson, Bengt R ^a   Nannmark, Ulf ^a   Goldfarb, Ronald H ^b,d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNT Health Sciences Center   (United States)

Author keywords

Interleukin 2 activated Natural Killer (A NK) cells; Matrix metalloproteinases (MMP); Tissue inhibitor of metalloproteinases (TIMP)

Indexed keywords

GELATINASE A; GELATINASE B; INTERLEUKIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE;

ARTICLE; CANCER LOCALIZATION; CELL MIGRATION; HUMAN; HUMAN CELL; IN VIVO STUDY; METASTASIS; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PROTEIN EXPRESSION;

EID: 0034069084     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Scripp CA, Simpson CG, White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 888-897, 1987.
2. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271: 907-913, 1994.
3. Kimura H, Yamaguchi Y: A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 80: 42-9, 1997.
4. Ganss R, Hanahan D: Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res 58: 4673-81, 1998.
5. Basse P, Herberman RB, Nannmark U, Johansson BR, Hokland M, Wasserman K, Goldfarb RH: Accumulation of adoptively transferred adherent"lymphokine-activated killer cells in murine metastases. J Exp Med 174: 479-488, 1991.
6. Basse PH, Nannmark U, Johansson BR, Herberman RB, Goldfarb RH: Establishment of cell-to-cell contact by adoptively transferred adherent lymphokine-activated killer cells with metastatic murine melanoma cells. J Natl Cancer Inst 83: 944-950, 1991.
7. Kitson RP, Appasamy PM, Nannmark U, Albertsson P, Gabauer MK, Goldfarb RH: Matrix metalloproteinases produced by rat IL-2 activated natural killer cells. J Immunol 160: 4248-4253, 1998.
8. Johansson BR, Unger ML, Albertsson P, Casselbrant A, Nannmark U, Hokland M: Infiltration and lysis of tumour cell aggregates by adherent interleukin-2-activated natural killer cells is distinct from specific cytolysis. Nat Immun 15: 87-97, 1996.
9. Goldfarb RH, Liotta LA: Proteolytic enzymes in cancer invasion and metastasis. Semin Thromb Hemost 12: 294-307, 1986.
10. Brown PD: Clinical studies with matrix metalloproteinase inhibitors. Apmis 107: 174-80, 1999.
11. Hagenaars M, Zwaveling S, Kuppen PJ, Ensink NG, Eggermont AM, Hokland ME, Basse PH, van de Velde CJ, Fleuren GJ, Nannmark U: Characteristics of tumor infiltration by adoptively transferred and endogenous natural-killer cells in a syngeneic rat model: implications for the mechanism behind anti-tumor responses. Int J Cancer 78: 783-9, 1998.
12. Yu AE, Hewitt RE, Connor EW, Stetler-Stevenson WG: Matrix metalloproteinases. Novel targets for directed cancer therapy. Drugs Aging 11: 229-44, 1997.
13. Xie B, Dong Z, Fidler IJ: Regulatory mechanisms for the expression of type IV collagenases/gelatinases in murine macrophages. J Immunol 152: 3637-44, 1994.
14. Trinchieri G, Perussia B: Human natural killer cells: biologic and pathologic aspects. Lab Invest 50: 489-513, 1984.
15. Brooks PC, Stromblad S, Sanders LC, von ST, Aimes RT, Stetler SW, Quigley JP, Cheresh DA: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85: 683-93, 1996.
16. Johnatty RN, Taub DD, Reeder SP, Turcovskicorrales SM, Cottam DW, Stephenson TJ, Rees RC: Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J Immunol 158: 2327-2333, 1997.